PFO
VTVT icon

Pathstone Family Office’s vTv Therapeutics VTVT Stock Holding History

Pathstone Family Office’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$116K Buy
+6,073
New +$149K ﹤0.01% 1573

Other funds holding VTVT

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
SQA
Simon Quick Advisors Morristown, New Jersey $2.19B AUM 17.29% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Pathstone Family Office's VTVT Position: Q3 2023 in Review

Pathstone Family Office opened a new position in vTv Therapeutics (VTVT) in Q3 2023: 6,073 shares worth $116K. The stake represents ﹤0.01% of the portfolio and ranks #1573 among its holdings.

24 funds tracked by Wall St. Rank hold VTVT as of Q3 2023.

  • Pathstone Family Office held 6,073 shares of vTv Therapeutics worth $116K as of Q3 2023.
  • vTv Therapeutics was a new Pathstone Family Office position in Q3 2023.
  • vTv Therapeutics made up ﹤0.01% of Pathstone Family Office's portfolio in Q3 2023, its #1573 holding.
  • 24 funds tracked by Wall St. Rank held vTv Therapeutics as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.